The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1169
ISSUE1169
November 10, 2003
Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection
November 10, 2003 (Issue: 1169)
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.